Live Breaking News & Updates on Myeloproliferative Neoplasm Program

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions. ....

Memorial Sloan Kettering Cancer Center , New York , United States , Prioty Islam , Raajitk Rampal , Alexanderp Boardman , Michaelj Mauro , Jan Philipp Bewersdorf , Myeloproliferative Neoplasms Program , Leukemia Service , Lymphoma Service , Myeloproliferative Neoplasm Program , International Prognostic Index , Science Summit , Memorial Sloan Kettering Cancer , Philipp Bewersdorf , Emerging Treatments , Cell Therapy , Non Hodgkin Lymphoma , Cart Cell Therapy , Myeloproliferative Neoplasms , Mantle Cell Lymphoma , Chronic Lymphocytic Leukemia , Hematologic Oncology ,